We are live on ! Find out more
IMI

Intermolecular, Inc.
IMI

Delisted

IMI was delisted on the 19th of September, 2019.

26 hedge funds and large institutions have $24M invested in Intermolecular, Inc. in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

8% more funds holding

Funds holding: 2426 (+2)

5% less capital invested

Capital invested by funds: $25.3M → $24M (-$1.34M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
26
Holders Change
+2
Holders Change %
+8.33%
% of All Funds
0.59%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
7
Increased
6
Reduced
4
Closed
5
Calls
Puts
Net Calls
Net Calls Change

IMI Hedge Fund Activity: Q1 2018 in Review

26 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Intermolecular, Inc. (IMI) for Q1 2018, worth a combined $24M — down 5.3% from $25.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new IMI positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Barclays, opening a new position worth an estimated $533K. The largest seller was Symmetry Peak Management, cutting an estimated $945K.

  • 26 institutional investors held Intermolecular, Inc. (IMI) as of Q1 2018, up from 24 in Q4 2017.
  • Funds reported $24M of Intermolecular, Inc. stock for Q1 2018, down 5.3% quarter-over-quarter.
  • 7 funds opened new Intermolecular, Inc. positions in Q1 2018 and 5 closed out, a net change of +2 holders.
  • The largest Intermolecular, Inc. buyer in Q1 2018 was Barclays, an estimated $533K added.
  • The largest Intermolecular, Inc. seller in Q1 2018 was Symmetry Peak Management, an estimated $945K sold.

Based on aggregated 13F filings for Q1 2018.